Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,685Revenue (TTM) $M363Net Margin (%)-1.6Altman Z-Score8.8
Enterprise Value $M1,577EPS (TTM) $-0.1Operating Margin %-1.2Piotroski F-Score7
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-1.8Higher ROA y-yY
Price/Book8.110-y EBITDA Growth Rate %--Quick Ratio2.0Cash flow > EarningsY
Price/Sales4.45-y EBITDA Growth Rate %--Current Ratio3.0Lower Leverage y-yY
Price/Free Cash Flow569y-y EBITDA Growth Rate %96.3ROA % (ttm)-1.9Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-3.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M64.8ROIC % (ttm)-3.3Gross Margin Increase y-yY

Gurus Latest Trades with NXTM

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NXTMJoel Greenblatt 2016-09-30 Sold Out $21.66 - $25.67
($23.31)
$ 26.0212%Sold Out0
NXTMJoel Greenblatt 2016-06-30 Buy $14.38 - $21.68
($17.8)
$ 26.0246%New holding18,781
NXTMRon Baron 2012-06-30 Sold Out -0.02%$14.94 - $19.44
($16.42)
$ 26.0258%Sold Out0
NXTMRon Baron 2012-03-31 Buy 0.02%$16.55 - $21.54
($17.89)
$ 26.0245%New holding176,418
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NXTM is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NXTM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Burbank Jeffrey HCEO 2017-01-18Sell7,500$27.63-5.83view
Brown Robert S.President, NxStage Kidney Care 2017-01-18Sell8,183$27.58-5.66view
Brown Robert S.President, NxStage Kidney Care 2017-01-17Sell10,805$27.72-6.13view
Burbank Jeffrey HCEO 2017-01-17Sell7,500$27.52-5.45view
Turk Joseph E JrPresident 2017-01-13Sell7,500$28-7.07view
Turk Joseph E JrPresident 2017-01-11Sell1,000$27.77-6.3view
TOWSE MATTHEW WSVP and Chief Financial Office 2016-12-20Sell4,300$25.551.84view
Swan Winifred LSVP and General Counsel 2016-12-15Sell3,500$25.910.42view
Burbank Jeffrey HCEO 2016-12-14Sell7,500$25.681.32view
Burbank Jeffrey HCEO 2016-12-13Sell7,500$25.422.36view

Quarterly/Annual Reports about NXTM:

News about NXTM:

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: MFLX, NXTM, CVRR, CMLP Nov 10 2013 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Jan 21 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Jan 20 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 17 2010 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 12,000 Shares Dec 16 2010 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 16 2010 

More From Other Websites
ETFs with exposure to NxStage Medical, Inc. : January 19, 2017 Jan 19 2017
NxStage® to Report Fourth Quarter and Full Year 2016 Financial Results Jan 16 2017
Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay Jan 04 2017
Illumina Fettered With Losses: Can It Bounce Back in 2017? Jan 03 2017
Masimo to Launch Advanced Monitoring Technologies in India Jan 03 2017
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3 Jan 02 2017
Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold? Jan 02 2017
Is Baxter Poised to Counter Low Cyclophosphamide Sales? Dec 30 2016
CryoLife (CRY) Now a Strong Buy on Solid Estimate Revisions Dec 30 2016
Alere (ALR) Appeals to Reinstate Medicare Billing Privilege Dec 30 2016
NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite Dec 30 2016
LabCorp: Covance Drug Prospects Bright, Competition Rife Dec 29 2016
ResMed: SDB Business Faces Risks, Reimbursement a Drag Dec 29 2016
Nutrisystem Declares Multi-Brand Marketing Approach for '17 Dec 29 2016
Myriad Genetics' Unit Releases Favorable Data on Vectra DA Dec 28 2016
Cardiovascular Systems (CSII): Q1 Solid, Net Losses Linger Dec 28 2016
5 Efficient Stocks to Strengthen Your Portfolio Dec 27 2016
Boston Scientific Down on Risks; Innovations Raise Hope Dec 27 2016
Qiagen Poised on Fundamentals, Expansion Plans on Track Dec 23 2016
Myriad Genetics: United Rheumatology Selects Vectra DA Test Dec 23 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)